Your browser doesn't support javascript.
loading
Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands.
Garritsen, F M; van den Heuvel, J M; Bruijnzeel-Koomen, C A F M; Maitland-van der Zee, A H; van den Broek, M P H; de Bruin-Weller, M S.
Afiliación
  • Garritsen FM; Department of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van den Heuvel JM; Department of Respiratory Disease, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Bruijnzeel-Koomen CAFM; Department of Dermatology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Maitland-van der Zee AH; Department of Respiratory Disease, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • van den Broek MPH; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
  • de Bruin-Weller MS; Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands.
J Eur Acad Dermatol Venereol ; 32(8): 1336-1342, 2018 Aug.
Article en En | MEDLINE | ID: mdl-29485224
BACKGROUND: Although atopic dermatitis (AD) is a very common skin disease, data on the percentage of patients with really difficult-to-treat AD are scarce. From socio-economic perspective, it is important to have more insight into these numbers, as new very effective, but expensive, treatment options will be available in the near future for difficult-to-treat AD. Estimating the number of patients with AD using oral immunosuppressive drugs can give an impression of the percentage of difficult-to-treat patients in the total AD population. OBJECTIVE: To give an overview of the use of oral immunosuppressive drugs in patients with AD in the Netherlands. METHODS: Prescription data of oral immunosuppressive drugs in the Netherlands were extracted from a pharmaceutical database (NControl) containing data of 557 million prescriptions and 7.2 million patients. An algorithm, based on the WHO Anatomical Therapeutic Chemical (ATC) codes, was used to identify patients with AD. The prescription of oral immunosuppressive drugs in patients with AD between 1 January 2012 and 1 January 2017 was evaluated. RESULTS: Based on the algorithm, 65 943 patients with AD were selected. 943 patients with AD (1.4%) used cyclosporine A, methotrexate, azathioprine or mycophenolic acid. Methotrexate was most commonly used, followed by azathioprine and cyclosporine A. A switch in medication was rarely seen. In the evaluation period, a decrease in the prescription of cyclosporine A was seen, together with an increase in the prescription of methotrexate. In 31% of the patients who stopped treatment, the discontinuation took place within the first months of treatment. CONCLUSION: In this study population, 1.4% of the patients with AD used oral immunosuppressive drugs for their eczema in a 5-year period. Methotrexate was the most commonly used systemic drug in the Netherlands for the treatment of AD.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prescripciones de Medicamentos / Dermatitis Atópica / Inmunosupresores Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prescripciones de Medicamentos / Dermatitis Atópica / Inmunosupresores Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido